Publications in collaboration with researchers from Hospital de Sagunto (2)

2009

  1. Prevalencia de enfermedad arterial periférica asintomática en pacientes con ictus isquémico no cardioembólico

    Neurologia, Vol. 24, Núm. 6, pp. 366-372

2004

  1. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study

    Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81